Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05189457
Title First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

prostate cancer

Therapies

Docetaxel + Triptorelin

Degarelix + Enzalutamide

Enzalutamide + Triptorelin

Docetaxel + Leuprolide

Docetaxel + Relugolix

Docetaxel + Goserelin

Degarelix + Docetaxel

Enzalutamide + Relugolix

Enzalutamide + Goserelin

Abiraterone + Leuprolide

Docetaxel + Tislelizumab

Enzalutamide + Leuprolide

Abiraterone + Goserelin

Abiraterone + Triptorelin

Abiraterone + Degarelix

Abiraterone + Relugolix

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.